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Abstract 
 
Objectives. This paper explores the use of regression models for estimating health 
status of schizophrenic patients, from a Bayesian perspective. Our aims are: 
1- To obtain a set of values of health states of the EQ-5D based on self-assessed 
health from a sample of schizophrenic patients.  
2- To analyse the differences in the health status and in patients’ perceptions of 
their health status between four mental-health districts in Spain.  
 
Methods. We develop two linear models with dummy variables. The first model 
seeks to obtain an index of the health status of the patients using a VAS as a 
dependent variable and the different dimensions of EQ-5D as regressors. 
The second model allows to analyse the differences between the self-assessed 
health status in the different geographic areas and also the differences between the 
patients’ self-assessed health states, irrespective of their actual health state, in the 
different geographic areas. 
The analysis is done using Bayesian approach with Gibbs sampling (computer 
program WinBUGS 1.4). 
Data concerning self-assessed EQ-5D with VAS from four geographic areas of 
schizophrenic patients were obtained for the purposes of this analysis.  
 
Results. We obtained the health status index for this sample and analysed the 
differences for this index between the four geographic areas. Our study reveals 
variables that explain the differences in patients’ health status and differences in 
their health states assessment. We consider four possible scenarios.  
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INTRODUCTION 
Clinical decisions cannot be made without a prior analysis of the cost and 
effectiveness of treatment, particularly for disorders with a high morbidity rate, 
such as schizophrenia. According to the 1993 World Bank report [1], although 
neuropsychiatry disorders constitute the second most prevalent non-infectious 
disease, they receive a disproportionately small allocation of resources in countries 
with a consolidated market economy. In Spain, the PSICOST group has 
contributed to developing a methodology to evaluate services and the costs arising 
from chronic mental illness in Spain [2-6]. 
In this work, which is part of a wider research on cost and effectiveness of 
treatment of schizophrenia carried out in Spain [7], we deal with the effectiveness 
side of the economic approach to the treatment of schizophrenia. We focus on the 
measurement of effectiveness through health indexes, with a specific concern on 
the appropriateness of using a single health index at national level, or if regional 
differences in the index, would they exist, should be taken into account when 
designing health care policy. We check for these interregional differences, and 
more specifically, for those in the health states valuations assigned by patients of 
different regions.  
The main finding of the paper is the verification not only of the existence of 
regional differences in health status of schizophrenic patients in our representative 
sample of the selected samples in 4 mental health care districts, but also in the 
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health states valuations that patients give to their health states. The relevance for 
policy making is that such differences should be taken into account in resource 
allocation and health care development in the treatment of schizophrenia.  
In this paper we use regression models to build up a value set of health states of the 
EQ-5D using Bayesian methods. Bayesian methodology allows to introduce 
previously obtained information in the parameters of the coefficients distributions. 
In our case, we use information from previous years to estimate the coefficients 
distributions, means and standard deviations. Our aims are, firstly, to obtain a set 
of values of health states of the EQ-5D based on self-assessed health from a 
sample of schizophrenic patients and, secondly, to analyse the differences in the 
health status and in patients’ perceptions of their health status between four 
mental-health districts in Spain.  
 
MATERIALS AND METHODS 
Health measurement 
For measurement of health purposes, we use a well established health instrument, 
the EQ-5D [8]. The EQ-5D questionnaire is a standardised, generic instrument 
concerning health-related quality of life for describing and valuing health that was 
designed by the EuroQol Group. It is a two part instrument. Part 1 records self-
reported problems for each of five domains: mobility (MO), self-care (SC), usual 
activities (UA), pain/discomfort (PD) and anxiety/depression (AD). Each domain 
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is divided into three levels of severity corresponding to no problem, some problem, 
and extreme problem. The combination of these levels defines a total of 243 health 
states. Part 2 records the subject’s self-assessed health on a Visual Analogue Scale 
(VAS), with a vertical 20 cm line on which the best and worst imaginable health 
states score 100 and 0, respectively. 
The aim of the EQ-5D is to generate a cardinal health index, that can be used in 
economic evaluation. Currently, the most widely used value set of the 243 health 
states of the EQ-5D was developed by Dolan [9] and it is being used in cost utility 
analysis of health care technologies and has been recommended in the UK by the 
National Institute for Clinical Excellence (NICE), the office of technology 
assessment of the National Health Service [10].  
Several models have been developed to obtain valuation sets for the health states of 
the EQ-5D. A functional form of dependence is specified that values the states of 
health of the individuals and the variables that compose the health index, obtained 
from the instrument of measure EQ-5D. The functional form is determined by a 
combination between the variables and an unknown set of coefficients. Regression 
models are used to assign values to those coefficients. 
Dolan [11] pioneered the building of an index of health from EQ-5D. In his work, 
it is shown the linear relationship between the value of the index and dummy 
variables corresponding to the different levels of each dimension of the EQ-5D, 
and incorporating a dummy additional variable (N3) with takes the value 1 when 
any dimension is at level 3, what can be interpreted as reflecting the decrease in 
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utility associated to “severe problems”. The use of relationships between the index 
and the different dimensions through coefficients allows, once obtained the 
coefficients estimation, to interpolate the values of the health states not observed 
directly, thus obtaining the value set of the 243 health states of EQ-5D. 
There are a great deal of studies in the literature that use the value set obtained by 
Dolan to get Quality Adjusted Life Years (QALYs), the health unit used in cost 
utility analysis. They usually not consider the possibility of existence of 
differences in the health states valuations between regions or countries, what could 
lead to bias in the analysis. 
Data 
Data analysed in this study were obtained from 4 small areas, selected as being 
representative of different socio-economic contexts and of different kinds of 
organization and availability of services. The four areas analysed in the study were 
in the provinces of Barcelona, Granada, Madrid and Navarre [12]. 
For each centre, we selected a representative sample of cases of schizophrenia, 
determined by the prevalence of cases treated. Criteria for inclusion in the study 
were: diagnosis of schizophrenia (DSM-IV diagnosis) [13], aged 18-65 years and 
having been in contact with the mental health treatment services in one of the 
selected areas within the six-month period designated for inclusion. After 
excluding patients with a primary diagnosis of neurological disorder or mental 
handicap, a sample of 356 patients was obtained. The patients were evaluated at 
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three instants: at the beginning of the study, after one year, and after two years. 
Because of the characteristic instability of the population, the number of patients 
for whom EQ-5D data were obtained was lower than the original sample, and this 
decreased further over time. We analysed only the observed data. 
Table 1. Healthcare area data of the four mental health care areas studied. 
Healthcare 
area Province Inhabitants Nº of patients Source data record 
Gavá Barcelona 135,000 86 
Gavá mental 
health centre 
Loja Granada 63,490 73 Schizophrenia cases in the South Granada area 
Salamanca Madrid 142,001 105 Psychiatric cases in the Madrid region 
Burlada Navarre 65,000 92 Navarre health information system (SISNA) 
Total - 405,491 356 - 
 
 
Table 2. Sampling Description. Mean (Standard Deviation) or Percentage (%). 
 Gavá Loja Salamanca Burlada TOTAL 
Female 31.4 21.9 33.3 37.0 31.5 
Age 37.5 (11.7) 37.8 (8.5) 36.8 (7.9) 40.4 (11.5) 37.9 
Age at onset 22.5 (6.3) 22.8 (6.4) 22.5 (6.5) 26.3 (6.5) 23.5 
Partner 20.9 9.6 10.5 14.1 13.8 
Employment 12.8 17.8 24.8 25.6 20.6 
Household 
Family 66.3 76.7 69.5 69.5 70.2 
TOTAL 86 73 105 92 356 
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Table 3. Patients of the sample responding to EQ-5D questionnaire. 
Nº of 
patients Province Year 1 Year 2 Year 3 
Gavá Barcelona 71 68 60 
Loja Granada 56 52 49 
Salamanca Madrid 72 46 38 
Burlada Navarre 78 69 64 
Total - 277 235 211 
 
 
Bayesian modelling 
This paper uses regression models to build up a value set of health states of the 
EQ-5D using Bayesian methods. Bayesian methodology allows to incorporate in 
the coefficients distributions information on the parameters previously obtained, 
through mean and standard deviation. In our study, we use information from 
previous periods.  
In Bayesian methodology, prior information on the parameters can be combined 
with data. Parameters are assumed to be random variables described by their 
probability distributions. The distribution that combines the prior distribution with 
data is known as posterior distribution. Browne and Draper (2000) [14] offer a 
detailed comparison of both types of models, classical and Bayesian. 
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In this work, we use non-informative prior distributions as a first approach to the 
problem for the first instant. We then use the posterior information from the first 
instant as the prior for the second. The same procedure is followed to obtain the 
posterior of the third. So, we adopt a bayesian sequential analysis to obtain the true 
value of the parameters. 
Bayesian estimation is done using Markov Chain Monte Carlo (MCMC) 
simulation techniques [15]. With MCMC simulation techniques, when the 
posterior distribution conditioned for a group of parameters has a known format, 
then it is possible to derive values for it directly. This process is known as Gibbs 
sampling and is used in the simulations in this work [16]. 
All computation and simulation was conducted with Gibbs sampling, implemented 
using the computer program WinBUGS1.4 [17]. We used there parallel chains and 
a single long chain for diagnostic assessment (checked using CODA software). A 
total of 100000 iterations were carried out (after a burn-in period of 10000), taking 
only a few minutes on a Pentium personal computer. 
 
Modelling 
We present two linear models with dummy variables. The aim of the first model is 
to obtain an index of the health status of the patients using a VAS as a dependent 
variable and the different dimensions of EQ-5D as regressors. 
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The second model concerns, firstly, to the differences between the self-assessed 
health states in the different geographic areas. For this purpose, we used the index 
obtained from Model 1 as the dependent variable, and dummies to represent the 
different geographic areas as regressors (Model 2.1). The second purpose of this 
model is to test the differences by geographic area in the patients’ self-assessed 
health states, irrespective of their actual health state. To do this, we used as the 
dependent variable the difference between the VAS and the index obtained in 
Model 1; the regressors, again, were dummies representing the different 
geographic areas (Model 2.2). 
Linear model with dummy variables (Model 1) 
Dummy variables are included to evaluate the move between levels 1 and 2 as 
compared to the move between levels 2 and 3. Two dummy variables are used for 
each dimension. In addition, a variable N3 is included. A similar model was used 
by Dolan and Greiner et al. [11, 18] Model 1: 
m i = β0 + MO2iβ1 + SC2iβ2 + UA2iβ3 + PD2iβ4 + AD2iβ5 + MO3iβ6 +  
SC3iβ7 + UA3iβ8 + PD3iβ9 + AD3iβ10 + N3iβ11  
          Model 1 
VASscore i  ~ N ( m i , Ωµ)  Ωµ~ Ga (a , b)  βj ~ N(β, Σ -1 ),  j =0,…,11 
The variables used in this model take the following values:  
MO2, SC2, UA2, PD2, AD2 = 1 if the score is 2; 0 otherwise. 
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MO3, SC3, UA3, PD3, AD3 = 1 if the score is 3; 0 otherwise. 
N3=1 if the score is 3 in one of the dimensions; 0 otherwise.  
When this model implies a lack of initial knowledge from non-informative prior 
distributions, this information is described by the following parameters: 
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The main diagonal of the matrix Σ -1 represents the precision of the parameters. 
This precision is defined by the inverse of the variance [17]. In the present study, a 
non-informative prior variance is taken as one for which there is a 95% probability 
that the value of the parameter lies in the range [-100, 100]. This is because the 
regressors are dummy variables (0, 1). Therefore, a variation of one unit in the 
latter should not increase (decrease) the dependent variable above (below) 100 
units. 
In order to incorporate the prior information, we transfer the posterior information 
from one regression as the prior information to another. The information is 
obtained by means of estimations of the mean and of the variance of the 
parameters, as follows: 
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where j
∧β  represents the estimated mean of parameter j with the information from 
the preceding periods, and where 
2
1
jsd
∧ represents the estimated precision 
associated with the parameter j.  
Linear Model with EQindex , and VASscore less EQindex as dependent variables (Model 
2) 
The dependent variable in Model 2.1 is EQindex and this is represented by:  
m i = β0 + Biβ1 + Giβ2 + Miβ3 
Model 2.1 
EQindex i  ~ N (m i , Ωµ)  Ωµ~ Ga (a , b)  βh ~ N(β, Σ -1 ),  h =0,…,3     
Where  B = 1 if the patient is from Barcelona; otherwise 0. 
 G = 1 if the patient is from Granada; otherwise 0. 
 M = 1 if the patient is from Madrid; otherwise 0. 
Dummy’s reference category N: (Navarre). 
We define EQindex as the dependent variable explained in Model 1 (
∧
VAS ). 
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Model 2.1 shows the differences in health status of the patients in the different 
areas, independently of whether the self-assessment of the patients in a given area 
by VAS is above (or below) the mean value. This is so because the index EQindex 
was calculated for all the patients with the estimations obtained for the whole 
sample. Thus, the estimated parameter i
∧β  represents the fact that the area i has 
patients who present a better health status (if it is positive), or a worse one (if it is 
negative) with respect to the reference area. 
Model 2.2 differs from Model 2.1 in the dependent variable, which is now VASscore 
i - EQindex i. This model shows the differences between areas between the health 
state and the value assigned to it. We can see whether the patients in a given area 
have different subjective perceptions of a given health state. Therefore, the 
estimated parameter i
∧β  represents the fact that a mean health state has a greater 
value, if positive (or a lesser one, if negative) for the patients in area i with respect 
to the assessment of the patients in the reference area. 
The dependent variable in Model 2.2 is what we are unable to explain from the 
VAS of the patients’ health status (Model 1). 
The prior information used in the estimation of Models 2.1 and 2.2 is included in 
the same way as in Model 1, as described above. 
 
 
 14
Models 2.1 and 2.2 present four possible scenarios: 
Scenario 1.  There are differences between the communities in Model 2.1, but not 
in Model 2.2. This is an index that is robust to regional changes. The different 
health states perceived are assessed equally, irrespective of the geographic area 
under study, and the index provides a good reflection of the relationship between 
health states and the assessment made by individuals by their VAS. 
Scenario 2. No differences between the areas are observed in Model 2.1, but they 
are in Model 2.2. This implies that individuals assess themselves differently in 
different areas. The same health states receive different assessments depending on 
the geographic area. For policy purposes, it seems that the index should include 
regional weights to compensate for this difference in assessments. 
Scenario 3. No differences are observed in either of the models. There are no 
regional changes in health states or in their assessment. We cannot affirm or deny 
the robustness of the index, because the health states that are assessed in the 
different areas are, on average, the same. 
Scenario 4. There are differences between the two models. This is a scenario that is 
complex to interpret, because we must consider the signs of these differences. For 
example, if there is a positive difference in Model 2.1 and a negative one in Model 
2.2 for a given area, this means that the area has, on average, better health states 
than the reference area, but that nevertheless, the patients, on their VAS, give 
themselves a worse assessment than do the patients in the reference area. 
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RESULTS 
Table 4 shows the estimations made using non-informative prior information, 
during the 3 years, with Model 1, for the sample of patients with schizophrenia. 
The model relates the VAS scale with the dimensions of the EQ-5D. Note that 
some of the estimated parameters have positive values, which could lead to 
inconsistencies on the EQ-5D index for worse health states with a higher score. 
Table 5 shows the estimations made, with Model 1, using the posterior information 
from year 1 as the prior information for year 2 and the posterior information from 
year 2 as the prior information for year 3. The final two columns, for year 3, 
contain full regression information, as they use the information from the three 
periods. In these columns, note that all the slopes, except two associated with the 
MO3 and UA3 dummies, are negative. The parameters associated with the MO3 
and UA3 dummies are the only ones that are positive, but their mean values are 
practically zero and, moreover, they have the lowest absolute value. It should be 
taken into account that whenever these dummies have a value of one, so does the 
N3 dummy. 
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Table 4. Model1. Simple linear model, VASscore as the dependent variable for each 
of the years with non-informative prior information. Posterior mean (standard 
deviation in parenthesis) and Bayesian credible Interval (BI). 
 Year 1 Year 2 Year 3 
 Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) 
CTE 70.35 (2.01) ( 66.42 , 74.28 ) 69.82 (2.23) ( 65.5 , 74.19 ) 73.52 (1.77) ( 69.99 , 76.96 ) 
MO2 -0.50 (3.30) ( -6.96 , 5.97 ) -1.13 (3.74) ( -8.55 , 6.27 ) -8.48 (3.09) ( -14.52 , -2.41 ) 
SC2 -7.03 (3.36) ( -13.63 , -0.35 ) -7.35 (3.78) ( -14.61 , 0.30 ) -5.02 (3.32) ( -11.50 , 1.47 ) 
UA2 -7.37 (2.73) ( -12.84 , -2.02 ) -6.45 (3.11) ( -12.52 , -0.37 ) 2.10 (2.79) ( -3.40 , 7.73 ) 
PD2 -5.56 (2.72) ( -10.89 , -0.24 ) -6.27 (3.06) ( -12.37 , -0.24 ) -5.36 (2.53) ( -10.45 , -0.40 ) 
AD2 -5.52 (2.71) ( -10.70 , -0.22 ) -4.96 (2.99) ( -10.95 , 0.99 ) -9.10 (2.46) ( -13.97 , -4.27 ) 
MO3 4.14 (6.54) ( -8.42 , 17.02 ) 6.35 (7.48) ( -8.36 , 20.84 ) -13.82 (8.10) ( -29.92 , 1.86 ) 
SC3 3.42 (8.54) ( -13.33 , 20.43 ) 3.96 (9.46) ( -14.63 , 22.45 ) -11.58 (8.92) ( -29.34 , 5.96 ) 
UA3 0.72 (6.47) ( -11.85 , 13.26 ) 2.31 (7.36) ( -12.44 , 16.64 ) 2.01 (7.07) ( -11.82 , 15.84 ) 
PD3 -10.40 (6.65) ( -23.36 , 2.68 ) -13.11 (7.39) ( -27.79 , 1.43 ) 3.36 (7.76) ( -11.80 , 18.85 ) 
AD3 -8.61 (6.11) ( -20.72 , 3.37 ) -8.73 (6.90) ( -22.37 , 4.70 ) -22.05 (6.85) ( -35.59 , -8.52 ) 
N3 -11.31 (6.31) ( -23.74 , 0.92 ) -11.57 (7.19) ( -25.68 , 2.47 ) -6.71 (7.00) ( -20.57 , 7.07 ) 
 
Table 5. Model1. Simple linear model, VASscore as the dependent variable for each 
of the years with informative prior information for years 2 and 3. Posterior mean 
(standard deviation in parenthesis) and Bayesian credible Interval (BI). 
 Year 1 Year 2 Year 3 
 Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) 
CTE 70.35 (2.01) ( 66.42 , 74.28 ) 70.18 (1.38) ( 67.51 , 72.90 ) 71.68 (1.03) ( 69.63 , 73.70 ) 
MO2 -0.50 (3.30) ( -6.96 , 5.97 ) -0.92 (2.41) ( -5.67 , 3.88 ) -2.53 (1.86) ( -6.18 , 1.16 ) 
SC2 -7.03 (3.36) ( -13.63 , -0.35 ) -7.23 (2.44) ( -11.92 , -2.34 ) -5.56 (1.92) ( -9.32 , -1.74 ) 
UA2 -7.37 (2.73) ( -12.84 , -2.02 ) -7.09 (1.98) ( -10.97 , -3.24 ) -3.79 (1.57) ( -6.87 , -0.67 ) 
PD2 -5.56 (2.72) ( -10.89 , -0.24 ) -5.86 (1.94) ( -9.74 , -2.06 ) -5.79 (1.47) ( -8.69 , -2.89 ) 
AD2 -5.52 (2.71) ( -10.70 , -0.22 ) -5.41 (1.88) ( -9.17 , -1.70 ) -5.69 (1.41) ( -8.44 , -2.95 ) 
MO3 4.14 (6.54) ( -8.42 , 17.02 ) 5.23 (4.81) ( -4.27 , 14.55 ) 2.11 (3.912) ( -5.57 , 9.70 ) 
SC3 3.42 (8.54) ( -13.33 , 20.43 ) 4.02 (6.22) ( -8.14 , 16.22 ) -1.02 (5.03) ( -10.93 , 8.89 ) 
UA3 0.72 (6.47) ( -11.85 , 13.26 ) 1.57 (4.43) ( -7.22 , 10.26 ) 0.91 (3.46) ( -5.811 , 7.78 ) 
PD3 -10.40 (6.65) ( -23.36 , 2.68 ) -11.90 (4.62) ( -21.04 , -2.89 ) -9.74 (3.80) ( -17.11 , -2.31 ) 
AD3 -8.61 (6.11) ( -20.72 , 3.37 ) -8.91 (4.08) ( -16.96 , -0.94 ) -11.22 (3.19) ( -17.61 , -4.81 ) 
N3 -11.31 (6.31) ( -23.74 , 0.92 ) -11.59 (3.81) ( -19.18 , -4.11 ) -12.73 (2.86) ( -18.30 , -7.02 ) 
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The constant in these models represents the mean of the VAS of the patients whose 
health state is 11111. In comparison with other studies carried out with sample 
groups from the general population [11, 18, 19] note that the patients with 
schizophrenia in this health state assess themselves, on average, as worse off than 
do the general population. 
Using the results from the model for year 3 with informative prior information, we 
obtain the values of the index EQindex for the 243 health states and, therefore, for 
each of the patients. For example, the value of the index for the health state 11223 
is obtained by CTE – UA2 – PD2 – AD3 – N3 = 71.68 – 3.79 – 5.79 – 11.22 – 
12.73 = 38.15. 
The Bayesian credible Intervals obtained through the marginal distributions of the 
coefficients, allow to know the range of variation from the value of the index with 
a probability of 95%. Thus, if variable MO2 takes value 1 and all other tangents 
take value 0, in the model for year 3 with informative prior information, the index 
would take a value of 69.15 and have a 95% probability of being between values 
65.5 – 72.84. 
Table 6 shows the results of the estimation with Model 2.1 with non-informative 
prior information for year 1 and informative information for the other two years. 
The dependent variable for this estimation was the index EQindex, obtained from the 
estimation of Model 1 in year 3 with prior information from the previous two 
years. 
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The constant represents the mean assessment of the index EQindex for the patients in 
Navarre. The other estimated coefficients show the deviation from the mean in the 
assessment of the index with respect to that obtained for Navarre. 
Table 6. Model 2.1. Regression Linear Model with EQindex to compare four 
geographic areas with prior information to year 2 and year 3. Posterior mean 
(standard deviation in parenthesis) and Bayesian credible Interval (BI). 
 
 Year 1 Year 2 Year 3 
 Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) 
CTE 57.05 (1.23) ( 54.59 , 59.42 ) 57.69 (0.75) ( 56.17 , 59.16 ) 58.29 (0.55) ( 57.19 , 59.36 ) 
B 6.00 (1.77) ( 2.52 , 9.48 ) 7.05 (1.18) ( 4.71 , 9.34 ) 6.40 (0.90) ( 4.65 , 8.19 ) 
G 2.67 (1.90) ( -1.03 , 6.49 ) 1.49 (1.29) ( -1.04 , 4.04 ) 2.20 (0.98) ( 0.24 , 4.14 ) 
M 2.62 (1.78) ( -0.89 , 6.12 ) 1.51 (1.27) ( -1.01 , 4.01 ) 1.73 (1.01) ( -0.26 , 3.73 ) 
 
Figure 1. Posterior probability distributions of the estimations associated with 
each of the areas in year 3 with prior information from the previous 2 years, in 
Model 2.1.  
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As the same weights were used to create the index, the differences found between 
the areas are caused by the patients’ different health states. 
The final column in Table 6 shows that the patients whose health states are the best 
are those of the patients from Barcelona. There is a 95% probability that their 
health states are between 4.65 and 8.19 points higher on the index EQindex than 
health states in Navarra. It should be taken into account that the highest value on 
this index is 71.68 and the lowest, 26.11, the values not being rescaled between 0 
and 100. 
Figure 1 shows the posterior probability distributions of the parameters of Model 
2.1 in year 3 with the prior information from the two previous years. The values of 
the estimations have been reconstructed for ease of interpretation. 
The overlapping of the distributions prevents us from stating that there are 
significant differences between health states in the geographic areas of Granada 
and Madrid. Note that in the area of Navarre health states are somewhat worse than 
in the other areas, while in Barcelona they are clearly superior.  
 
Table 7 gives the results of the estimation by Model 2.2, with non-informative 
prior information in year 1 and informative information for the other two years. 
The dependent variable for this estimation was VASscore - EQindex.  
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Table 7. Model 2.2. Regression Linear Model with VAS without EQindex to 
compare four geographic areas with prior information to years 2 and 3. 
 
 Year 1 Year 2 Year 3 
 Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) Mean (sd) BI ( 95% ) 
CTE 0.765 (2.21) ( -3.66 , 5.02 ) 1.30 (1.20) ( -1.10 , 3.64 ) 2.04 (0.89) ( 0.28 , 3.76 ) 
B -0.48 (3.19) ( -6.75 , 5.78 ) -2.39 (1.87) ( -6.11 , 1.22 ) -0.95 (1.44) ( -3.75 , 1.88 ) 
G -3.30 (3.43) ( -9.96 , 3.58 ) -5.33 (2.04) ( -9.34 , -1.34 ) -5.42 (1.57) ( -8.54 , -2.32 ) 
M -5.38 (3.22) ( -11.73 , 0.93 ) -1.64 (2.04) ( -5.68 , 2.32 ) -0.76 (1.62) ( -3.99 , 2.44 ) 
 
 
Figure 2. Posterior probability distributions of the estimations associated with 
each of the areas in year 3, with prior information from the two previous years, in 
Model 2.2.  
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The final column of Table 7 shows that the patients in Granada assessed 
themselves below the mean value, at a 95% probability. As regards the other areas, 
no important differences were found in assessments of health status. 
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Figure 2 shows the posterior probability distributions of the parameters of Model 
2.2 in year 3, with prior information about the two previous years. The values of 
the estimations have been reconstructed for ease of interpretation. A positive value 
on the ordinate axis means an over-assessment of the health states of the patients in 
a given area with respect to the mean, while a negative value implies a 
corresponding under-assessment. 
Tables 6 & 7 and Figures 1 & 2 enable us to analyse the different scenarios that 
may occur in some areas with respect to others. This analysis is summarised in 
Table 8, which shows that 4 such scenarios are possible: 
Scenario 1: Comparison of Navarre and Madrid with Barcelona. There are 
differences in health states, but not in individuals’ assessments. This would 
indicate that our index is robust. This conclusion, however, cannot be generalised, 
because of the great diversity of scenarios found. 
Scenario 2: The case of Granada vs. Madrid, in which health states, on average, 
are practically identical, and where, nevertheless, the assessments made by patients 
differ between the areas. 
Scenario 3: This is the case we find on comparing Madrid with Navarre. The 
samples are homogeneous regarding both actual health states and their assessment 
by the patients. 
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Scenario 4: No conclusions can be drawn, because in one situation, the patients 
with better health status report higher assessments (as in the case of Barcelona vs. 
Granada), but the opposite is true in another, as is the case of Granada vs. Navarre.  
Table 8. Differences between areas with a 95% probability. 
 
Areas Model 2.1 Model 2.2 Scenarios 
B vs G Y Y Scenario 4 
     vs M Y N Scenario 1 
      vs N Y N Scenario 1 
G vs M N Y Scenario 2 
      vs N Y Y Scenario 4 
M vs N N N Scenario 3 
Y = If differences exist at 95% probability 
N = No differences at 95% probability 
 
DISCUSSION 
The differences by region or by country should be taken into account when EQ-5D 
is to be used as an index of quality of life. The present study shows that there are 
differences in the assessment of health states between different areas. Transferring 
the values of an index to another geographic area, or to another country, without 
taking into account such assessment differences could lead to erroneous 
conclusions being drawn. 
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From the annual development of Models 2.1 and 2.2, we can state that patients 
present great stability by geographic areas concerning variations in health states, 
and a great instability as regards their VAS assessment, independently of their 
actual health state. 
For informative prior information, we used that from the previous period or 
periods. To include this information, it was only necessary to estimate the mean 
and the standard deviation. This procedure has been carried out to facilitate the use 
of all existing information from the sample, thus obtaining more robust results in 
the coefficients estimation.  
The prior information used was that available for previous years, except for the 
first year, when non-informative prior distribution data were used. Prior non-
informative distributions were used in this study due to the lack of initial 
knowledge about the distribution of the prior parameters in other studies.  
There are several studies showing the use of the instrument EQ-5D in 
schizophrenic patients in Spain [20-22] and other countries [23-26]. But we lack an 
index specifically obtained for schizophrenia. This leads some authors to use 
indexes from general population, and even from general population of other 
countries. Looking at our results that confirm the existence of differences in 
valuation between regions, it seems that the results of those studies could not be 
adequate. 
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Limitations of the study 
Some limitations should be mentioned. First, sample size is relatively small. 
Second, we do not discuss about variables that could affect the quality of life, such 
as sociodemographic characteristics or differences in service availability, which 
could be different between the different areas and thus affect the quality of life of 
the patients. It should be noted, though, that the sample is representative of every 
catchment area included in the analysis. This is particularly relevant in Spain, 
where mental health care is provided by sectors. Furthermore, every case included 
in the study was re-assessed by an external researcher previously standardised in 
the assessment battery used in this study. 
CONCLUSION 
Our results could have important implications for health policy. The knowledge of 
geographical differences in the health status of schizophrenic patients, as well as in 
the assessment of the health states can contribute to a better assessment of need 
and to a better policy design. 
It may be more reliable for the purpose of economic evaluations an index that 
measures quality of life through EQ-5D obtained for a specific geographical zone, 
even when using a smaller sample, than doing the analysis using the value set of a 
different population.  
As a reflection for further research, it might be interesting to analyse whether the 
effect of each of the explicative variables on health status varies between 
geographic areas.  
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Key issues 
* The EQ-5D questionnaire is a standardised, generic instrument concerning 
health-related quality of life for describing and valuing health aiming at obtaining a 
health unit, useful in economic evaluation.  
* A Bayesian approach can incorporate prior knowledge on parameters through 
specification of prior distribution or incorporating prior empirical evidence on the 
parameters, thus getting more robust results.  
* There are differences in the health status of schizophrenic patients and in 
patients’ valuations of their health status between four mental-health districts in 
Spain. 
* The relevance for policy making is that such differences should be taken into 
account in resource allocation and health care development in the treatment of 
schizophrenia.  
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